Synthesis, Antiproliferative, and Antioxidant Evaluation of 2-Pentylquinazolin-4(3H)-One(Thione) Derivatives with DFT Study

Total Page:16

File Type:pdf, Size:1020Kb

Synthesis, Antiproliferative, and Antioxidant Evaluation of 2-Pentylquinazolin-4(3H)-One(Thione) Derivatives with DFT Study molecules Article Synthesis, Antiproliferative, and Antioxidant Evaluation of 2-Pentylquinazolin-4(3H)-one(thione) Derivatives with DFT Study Amira A. El-Sayed 1, Mahmoud F. Ismail 1 , Abd El-Galil E. Amr 2,3,* and Ahmed M. Naglah 2,4 1 Department of Chemistry, Faculty of Science, Ain Shams University, 11566 Abbassia, Cairo 11566, Egypt; [email protected] (A.A.E.-S.); [email protected] (M.F.I.) 2 Pharmaceutical Chemistry Department, Drug Exploration & Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; [email protected] 3 Applied Organic Chemistry Department, National Research Center, Cairo, Dokki 12622, Egypt 4 Peptide Chemistry Department, Chemical Industries Research Division, National Research Centre, Dokki, Cairo 12622, Egypt * Correspondence: [email protected]; Tel.: +966-543074312 Academic Editor: Qiao-Hong Chen Received: 5 October 2019; Accepted: 20 October 2019; Published: 21 October 2019 Abstract: The current study was chiefly designed to examine the antiproliferative and antioxidant activities of some novel quinazolinone(thione) derivatives 6–14. The present work focused on two main points; firstly, comparing between quinazolinone and quinazolinthione derivatives. Whereas, antiproliferative (against two cell lines namely, HepG2 and MCF-7) and antioxidant (by two methods; ABTS and DPPH) activities of the investigated compounds, the best quinazolinthione derivatives were 6 and 14, which exhibited excellent potencies comparable to quinazolinone derivatives 5 and 9, respectively. Secondly, we compared the activity of four series of Schiff bases which included the quinazolinone moiety (11a–d). In addition, the antiproliferative and antioxidant activities of the compounds with various aryl aldehyde hydrazone derivatives (11a–d) analogs were studied. The compounds exhibited potency that increased with increasing electron donating group in p-position (OH > OMe > Cl) due to extended conjugated systems. Noteworthy, most of antiproliferative and antioxidant activities results for the tested compounds are consistent with the DFT calculations. Keywords: quinazolin-4(3H)-one; quinazolin-4(3H)-thione; Schiff base; antiproliferative activity; antioxidant activity; DFT study 1. Introduction Cancer is the second leading cause of death globally, and the contribution of cancer disease to the overall mortality rate is increasing. Economically, the total annual cost of cancer in 2010 was estimated at approximately US$ 1.16 trillion [1]. So that, more rational design, synthesis, and evaluation of new compounds as anticancer, with higher efficiency is considered as urgent mission in the medicinal chemistry field. Quinazoline and quinazolinone derivatives are considered as tremendous targets for the medicinal chemists, due to the fact that they are the scaffold of different potent anticancer drugs, such as Gefitinib (trade name Iressa®), Erlotinib (trade name Tarceva®)[2–4], Methaqualone [5], Afloqualone (as anticonvulsant activity) [6,7], Chloroqualone (as antitussive), and Diproqualone (as sedative-hypnotic agents) [8] (Figure1). Molecules 2019, 24, 3787; doi:10.3390/molecules24203787 www.mdpi.com/journal/molecules Molecules 2019, 24 2 Molecules 2019, 24, 3787 2 of 19 Molecules 2019, 24 2 Figure 1. Some structures of synthetic drugs scaffold quinazoline and quinazolinone derivatives. FigureFigure 1. Some 1. Some structures structures of of synthetic synthetic drugs drugs scascaffoldffold quinazoline quinazoline and and quinazolinone quinazolinone derivatives. derivatives. In the last decades and until now, various compounds including quinazolinone moiety In the last decades and until now, various compounds including quinazolinone moiety conspicuouslyIn the last exhibited decades broad and spectrum until now, in variousnumerous compounds pharmacological including activities quinazolinone such as anticancer moiety conspicuously exhibited broad spectrum in numerous pharmacological activities such as anticancer conspicuously[9–14], anticonvulsants exhibited [15], broad antiproliferative spectrum in[16], numerous anti‐inflammatory pharmacological [17], antihypertensive activities such [18], as [9–14],[9–14], anticonvulsants anticonvulsants [15], [15], antiproliferative antiproliferative [16],[16], antianti‐‐inflammatoryinflammatory [17], [17], antihypertensive antihypertensive [18], [18], anticancer [9–14], anticonvulsants [15], antiproliferative [16], anti-inflammatory [17], antifungalantifungal [19], [19], antibacterial, antibacterial, antioxidant antioxidant [20], [20], antimicrobialantimicrobial [21], [21], anti anti‐allergic‐allergic [22], [22], antimalarial antimalarial [23], [23], antihypertensive [18], antifungal [19], antibacterial, antioxidant [20 ], antimicrobial [21], anti-allergic [22], antileishmanialantileishmanial [24], [24], and and treatment treatment of of Alzheimer’s Alzheimer’s disease (AD) (AD) [25]. [25]. antimalarialGenerally,Generally, [23 ],the antileishmanial thenatural natural products products [24], andare are treatment consideredconsidered of as Alzheimer’sas oneone of of the the diseasemost most interesting (AD) interesting [25 ].sources sources of of biologicallyGenerally,biologically active the active naturalcompounds. compounds. products Among Among are considered them, them, naturallynaturally as one occurringoccurring of the most quinazolin quinazolin interesting‐4(3‐4(3H sources)‐oneH)‐ onederivatives, of derivatives, biologically activewhichwhich compounds.can canbe isolatedbe isolated Among from from them,various various naturally plants plants andand occurring microorganisms quinazolin-4(3 such such asH )-oneasLuotonin Luotonin derivatives, A (sources;A (sources; which canPeganum bePeganum isolated nigellastrum nigellastrum from various) )[26],[26], plants 2‐2(heptan‐(heptan and microorganisms‐3‐3‐‐yl)quinazolinoneyl)quinazolinone such (sources;(sources; as Luotonin BacillusBacillus A (sources;cereus cereus) [27],Peganum) [27], Dictyoquinazol A (sources; Dictyophora indusiata) [28], and Echinozolinone (sources; Echinops nigellastrumDictyoquinazol)[26 ],A 2-(heptan-3-yl)quinazolinone (sources; Dictyophora indusiata (sources;) [28],Bacillus and cereus Echinozolinone)[27], Dictyoquinazol (sources; A Echinops (sources; echinatus) [29] (Figure 2). Dictyophoraechinatus) [29] indusiata (Figure)[ 2).28 ], and Echinozolinone (sources; Echinops echinatus)[29] (Figure2). Figure 2. Some structures of naturally occurring quinazolin‐4(3H)‐one derivatives. Figure 2. Some structures of naturally occurring quinazolin quinazolin-4(3‐4(3H)-one)‐one derivatives. Quinazolinones have been synthesized by different methodologies [28,30–37], in the present study, the conventional methodology to construct novel qunizolinone compounds has been Quinazolinones have been synthesized by different different methodologies [28,30–37], [28,30–37], in the present Quinazolinonesadopted, followed have by thebeen study synthesized of the antiproliferative by different methodologiesactivity, antioxidant [28,30–37], activity, inand the DFT present study, thethe conventional conventional methodology methodology to constructto construct novel novel qunizolinone qunizolinone compounds compounds has been has adopted, been study,calculations the conventional for the synthesized methodology compounds. to construct novel qunizolinone compounds has been followedadopted, byfollowed the study by of the the antiproliferativestudy of the antiproliferative activity, antioxidant activity, activity, antioxidant and DFT calculationsactivity, and for DFT the synthesizedcalculations2. Results compounds.for and the Discussion synthesized compounds. 2. Results 2.1. Chemistry and Discussion 2.1. ChemistryIn this interesting work, curing of anthranilic acid 1 with hexanoyl chloride 2 in dry pyridine 2.1. Chemistryafforded the corresponding N‐hexanoyl derivative 3 [38], which was cyclized by heating in distilled Inacetic this anhydride interesting to give work, 2‐pentyl curing‐4H of‐benzo[ anthranilicd][1,3]oxazin acid ‐14‐withone 4 hexanoyl[39,40] (Scheme chloride 1). 2 in dry pyridine In this interesting work, curing of anthranilic acid 1 with hexanoyl chloride 2 in dry pyridine afforded the corresponding N-hexanoyl derivative 3 [38], which was cyclized by heating in distilled afforded the corresponding N‐hexanoyl derivative 3 [38], which was cyclized by heating in distilled acetic anhydride to give 2-pentyl-4H-benzo[d][1,3]oxazin-4-one 4 [39,40] (Scheme1). acetic anhydride to give 2‐pentyl‐4H‐benzo[d][1,3]oxazin‐4‐one 4 [39,40] (Scheme 1). Scheme 1. The strategy for synthesis of compound 4. Scheme 1. The strategy for synthesis of compound 4.4. Molecules 2019, 24, 3787 3 of 19 Molecules 2019, 24 3 Benzoxazinone derivative derivative 44 waswas utilized in in situ as a precursor to construct new quinazolinone derivatives. For For instance, instance, reaction reaction of of benzoxazinone benzoxazinone derivative derivative 44 withwith formamide formamide afforded afforded 1 22-pentylquinazolin-4(3‐pentylquinazolin‐4(3HH))-one‐one 55 [41][41 ](Scheme (Scheme 2).2). The The 1H NMRH NMR spectrum spectrum of 5 exhibited of 5 exhibited a singlet a singlet peak atpeak 12.13 at 12.13 ppm ppm exchangeable exchangeable with with D2O D corresponding2O corresponding to NH to NH proton, proton, two two doublet doublet and and two two triplet peaks in the aromatic region at 8.05–7.42 ppm corresponding to four aromatic protons, and four characteristic peaks upfield upfield at 2.56–0.84 ppm for n-pentyl‐pentyl protons. Afterwards, sulfurationsulfuration
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • The Two Tonttituntivi Da Ti on and Main
    THETWO TONTTITUNTIVIUS 20180264013A1 DA TI ON AND MAIN ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0264013 A1 DILL ( 43 ) Pub . Date : Sep . 20 , 2018 ( 54 ) COMPOSITION AND METHODS FOR Publication Classification TREATING SLEEP DISORDERS (51 ) Int. CI. A61K 31 /60 (2006 . 01 ) ( 71 ) Applicant: WELLESLEY A61K 31 / 4025 ( 2006 .01 ) PHARMACEUTICALS , LLC , A61K 45 / 06 ( 2006 .01 ) Newtown , PA (US ) A61K 31 /616 ( 2006 . 01 ) A61K 31/ 4725 ( 2006 . 01 ) (72 ) Inventor : David A . DILL , Newtown , PA (US ) A61K 31 / 46 (2006 .01 ) A61K 31/ 405 ( 2006 .01 ) A61K 9 / 00 ( 2006 .01 ) (21 ) Appl. No. : 15 /985 ,315 A61K 31 /216 ( 2006 . 01 ) A61K 31 / 192 (2006 . 01 ) ( 22 ) Filed : May 21 , 2018 A61K 31 / 19 ( 2006 .01 ) A61K 31 / 167 (2006 . 01 ) A61K 31 / 12 ( 2006 .01 ) Related U . S . Application Data (52 ) U . S . CI. @(63 ) Continuation - in -part of application No. 14 / 172, 649 , CPC . .. .. A61K 31 /60 (2013 . 01 ) ; A61K 31 /4025 filed on Feb . 4 , 2014 , which is a continuation of ( 2013 .01 ) ; A61K 45 / 06 ( 2013 .01 ) ; A61K application No . 13 / 847 , 927 , filed on Mar. 20 , 2013 , 31 /616 ( 2013 . 01 ) ; A61K 31 /4725 ( 2013 .01 ) ; now Pat . No . 8 ,685 , 453 , which is a continuation of A61K 31/ 46 ( 2013 .01 ) ; A61K 2300 /00 application No. 13 / 560 ,607 , filed on Jul. 27 , 2012 , ( 2013 .01 ) ; A61K 9 /0002 ( 2013 . 01 ) ; A61K now Pat. No. 8 ,445 , 015 , which is a continuation of 31 / 216 ( 2013 .01 ) ; A61K 31/ 192 ( 2013 . 01 ) ; application No. 13 / 487, 348 , filed on Jun .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • The Effortless Sleep Method: Cure for Insomnia
    Sleeping Pills: An Introduction 1 1 Sleeping Pills: An Introduction What Are Sleeping Pills? Most sleeping pills are “sedative hypnotics.” That’s a specific class of drugs used to induce and/or maintain sleep. Sedative hypnotics include benzodiazepines, barbiturates, and various hypnotics. SLEEPING PILL ABUSE: ITS SIGNS AND SYMPTOMS A number of people underestimate the powerful grip sleeping pills like Ambien or Sonata can have over someone’s life and the dangers of abusing these drugs. 2 The Effortless Sleep Method: Cure for Insomnia... Many people abusing sleeping pills experience memory and concentration problems. Some of the signs of sleeping pill abuse include: • Slurred speech • Uncoordinated movements • Unsteady gait • Inability to focus • Impaired memory • Unusual euphoria. SLEEPING PILLS: ITS MAIN DANGERS Both the immediate and long-term dangers of sleeping pill abuse are enough for most people to exercise caution when using them. However, many people aren’t aware of the dangers of these medications. The dangerous effects of sleep medications range from seizures to depressed breathing. Some people also experience allergic reactions from sleeping pills that can cause difficulty breathing, chest pain, nausea and swelling. Though rare, people who use sleeping pills may even develop parasomnias. Parasomnias are defined as sleep disorders that include behaviors like sleep-walking, sleep-eating, sleep-sex, sleep- driving and other potentially dangerous sleep-related activities. The immediate dangers of sleeping pills range from minor fatigue to coma. Some of these side effects can even lead to deadly overdoses, casting light on the true dangers of sleeping pills. Common symptoms of sleeping pill abuse are: • Dizziness • Dry mouth • Difficulty with coordination • Daytime drowsiness • Memory loss • Unusual dreams • Itching and swelling Sleeping Pills: An Introduction 3 • Lightheadedness • Depressed breathing rate.
    [Show full text]
  • METAL-FREE SYNTHESIS of 2,3-DIHYDROQUINAZOLINONE DERIVATIVES USING 5-SULFOSALICYLIC ACID AS an ORGANOCATALYST Chandrakant D
    Bhenki et al RJLBPCS 2020 www.rjlbpcs.com Life Science Informatics Publications Original Research Article DOI: 10.26479/2020.0602.04 METAL-FREE SYNTHESIS OF 2,3-DIHYDROQUINAZOLINONE DERIVATIVES USING 5-SULFOSALICYLIC ACID AS AN ORGANOCATALYST Chandrakant D. Bhenki1, 2*, Shrikrishna S. Karhale1, Kiran N. Patil3, Vasant B. Helavi1 1. Department of Chemistry, Rajaram College, Kolhapur, (M.S.), India. 2. Department of Chemistry, Shri S. H. Kelkar College, Devgad, Sindhudurg, (M.S.), India. 3. Department of Chemistry, Dr.Ghali College, Gadhinglaj, Kolhapur, (M.S.), India ABSTRACT: An efficient, selective and green protocol for the synthesis of 2,3- dihydroquinazolinone derivatives developed by the reaction of 2-aminobenzamide and aromatic aldehydes under metal-free conditions using 5-sulfosalicylic acid (5-SSA) as an organocatalyst in ethanol - water (1:1,v/v) system. The main advantages of this procedure include the use of an organocatalyst, practical simplicity, high yields, eco-friendly solvent, atom economy and ease of isolation of the product. Keywords: Organocatalyst, Metal-free synthesis, High atom economy,2,3-dihydroquinazolinones, Green protocol etc. Article History: Received: March 10, 2020; Revised: March 29, 2020; Accepted: April 15, 2020. Corresponding Author: Mr. Chandrakant D. Bhenki* Department of Chemistry, Shri S. H. Kelkar College, Devgad, Sindhudurg, Pin.: 416613, (M.S.), India, Email address: [email protected] 1.INTRODUCTION In several important natural and synthetic organic derivatives, the quinazolinone ring is observed.[1]
    [Show full text]
  • Quinazolinone Derivatives As An
    inal chem ic is d t Abulkhair et al., Med Chem (Los Angeles) 2016, 6:9 e r M y Medicinal chemistry DOI: 10.4172/2161-0444.1000404 ISSN: 2161-0444 t Research Article Open Access Molecular Docking, Synthesis and Biological Evaluation of Some Novel 2-Substituted-3-allyl-4(3H)-quinazolinone Derivatives as Anticonvulsant Agents Hamada S Abulkhair1, Kamal M El-Gamal1,2, Khaled El-Adl3* and Mohamed F Fadl4 1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11884, Cairo, Egypt 2Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy and Pharmaceutical Industries, Delta University, Mansoura, Egypt 3Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11884, Cairo, Egypt 4Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City 11884, Cairo, Egypt Abstract A new series of 2-substituted-3-allyl-4(3H)-quinazolinone derivatives (4a-e-8a-d) were synthesized and evaluated for their anticonvulsant activity against pentylenetetrazole (PTZ)-induced seizures and maximal electroshock test in mice and compared with the reference drugs methaqualone and sodium valproate. The neurotoxicity was assessed using rotarod test. The molecular modeling was performed for all synthesized compounds to predict their binding affinity towards GABA-A receptor as a proposed mode of their anticonvulsant activity. The data obtained from the molecular docking was strongly correlated with that obtained from the biological screening which revealed that; compounds 4c, 4b and 4d showed the highest binding affinities towards GABA-A receptor and also showed the highest anticonvulsant activities in experimental mice with relatively low neurotoxicity and low toxicity in the median lethal dose test when compared with the reference drugs.
    [Show full text]
  • WO 2013/170195 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/170195 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61L 24/04 (2006.01) A61K 9/127 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (21) International Application Number: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, PCT/US20 13/0406 19 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (22) International Filing Date: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 10 May 2013 (10.05.2013) ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/646,227 11 May 2012 ( 11.05.2012) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/669,577 9 July 2012 (09.07.2012) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 61/785,358 14 March 2013 (14.03.2013) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: MEDICUS BIOSCIENCES, LLC [US/US]; ML, MR, NE, SN, TD, TG).
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]